Helen Tayton-Martin
2021
Compensation breakdown
| Non-Equity Incentive Plan | $198,534 |
|---|---|
| Option Awards | $1,069,101 |
| Salary | $464,408 |
| Other | $46,893 |
| Total | $1,778,936 |
Tayton-Martin received $1.1M in option awards, accounting for 60% of the total pay in 2021.
Tayton-Martin also received $198.5K in non-equity incentive plan, $464.4K in salary and $46.9K in other compensation.
Rankings
In 2021, Helen Tayton-Martin's compensation ranked 6,512th out of 12,415 executives tracked by ExecPay. In other words, Tayton-Martin earned more than 47.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,512 out of 12,415 | 48th |
Division Manufacturing | 2,795 out of 5,505 | 49th |
Major group Chemicals And Allied Products | 1,233 out of 2,375 | 48th |
Industry group Drugs | 1,100 out of 2,096 | 48th |
Industry Biological Products, Except Diagnostic Substances | 263 out of 449 | 41st |
Pay ratio
| Helen Tayton-Martin's Pay | $1,778,936 |
|---|---|
| Median Employee's Pay | $126,493 |
| Pay Ratio | 14to 1 |
In 2021, the annual total compensation of Helen Tayton-Martin was $1,778,936.
The annual total compensation of the median employee at Adaptimmune Therapeutics was $126,493.
The ratio of Helen Tayton-Martin's pay to the pay of median employee was therefore 14 to one.
Tayton-Martin's colleagues
We found four more compensation records of executives who worked with Helen Tayton-Martin at Adaptimmune Therapeutics in 2021.